Trametinib is an orally available highly specific inhibitor of MEK that had been approved for clinical treatment for advanced melanoma, anaplastic thyroid cancer and non-small-cell lung cancer [35–37]. Here, MAP2K7 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.